尿激酶原预处理联合PTCA治疗急性心肌梗死患者的效果  

Effects of PTCA on patients with acute myocardial infarction after prourokinase pretreatment

作　　者：朱璐燕 ZHU Luyan(Department of Cardiology of Baofeng County People’s Hospital,Pingdingshan 467400 Henan,China)

机构地区：[1]宝丰县人民医院心血管内科,河南平顶山467400

出　　处：《中国民康医学》2023年第2期15-18,共4页Medical Journal of Chinese People’s Health

摘　　要：目的:观察尿激酶原预处理联合经皮冠状动脉腔内成形术(PTCA)治疗急性心肌梗死(AMI)患者的效果。方法:回顾性分析2019年1月至2021年1月该院收治的85例AMI患者的临床资料,按不同治疗方案分为观察组43例和对照组42例。对照组行PTCA治疗,观察组在对照组基础上采用尿激酶原预处理治疗,比较两组心肌梗死溶栓试验(TIMI)血流分级、心功能指标[左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)]水平、血清心型脂肪酸结合蛋白(HFABP)水平、凝集蛋白-1(ITLN-1)水平和主要心血管不良事件(MACE)发生率。结果:术后,观察组TIMI血流分级优于对照组,差异有统计学意义(P<0.05);术后1个月,观察组LVEF、ITLN-1水平高于对照组,LVEDD、HFABP水平低于对照组,差异有统计学意义(P<0.05);观察组MACE发生率为9.30%,低于对照组的40.48%,差异有统计学意义(P<0.05)。结论:尿激酶原预处理联合PTCA治疗AMI患者可改善TIMI血流分级、心功能指标水平,提高ITLN-1水平,降低HFABP水平和MACE发生率,效果优于单纯PTCA治疗。Objective: To observe effects of percutaneous transluminal coronary angioplasty(PTCA) on patients with acute myocardial infarction(AMI) after prourokinase pretreatment. Methods: The clinical data of 85 patients with AMI admitted to the hospital from January 2019to January 2021 were retrospectively analyzed. According to different treatment options, they were divided into observation group(43 cases) and control group(42 cases). The control group was treated with PTCA, while the observation group was treated with prourokinase pretreatment on the basis of that of the control group. The TIMI blood flow grade, the cardiac function index levels [left ventricular ejection fraction(LVEF), left ventricular end-diastolic diameter(LVEDD)], the serum heart-type fatty acid-binding protein(HFABP) level, the intelectin-1(ITLN-1) level, and the incidence of major adverse cardiovascular events(MACE) were compared between the two groups. Results: After the surgery, the TIMI blood flow grade of the observation group was better than that of the control group, and the difference was statistically significant(P<0.05). 1 month after the surgery, the levels of LVEF and ITLN-1 in the observation group were higher than those in the control group, the levels of LVEDD and HFABP were lower than those in the control group, and the differences were statistically significant(P<0.05). Further, the incidence of MACE in the observation group was 9.30%, which was lower than 40.48% in the control group, the difference was statistically significant(P<0.05). Conclusions: PTCA after prourokinase pretreatment can improve the TIMI blood flow grade and the cardiac function index levels, increase the ITLN-1 levels, and reduce the HFABP levels and the incidence of MACE in the patients with AMI. Moreover, it is superior to single PTCA.

关 键 词：尿激酶原 经皮冠状动脉腔内成形术 急性心肌梗死 TIMI血流分级 左心室射血分数 左心室舒张末期内径 心型脂肪酸结合蛋白 

分 类 号：R541.4[医药卫生—心血管疾病]